Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

New clues about why the eye's iris sheds in pigmentary glaucoma (opens in a new tab)

medicalxpress.com · 2026-11-03

Short answerEvidenceSource

Short answer

Mixed

Mixed.

One claim goes further than the study. 2 other points were not covered by the paper.

  • 2 supported
  • 1 overstated
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

One claim overstates the study. Two of five check out. Two claims the study doesn't address.

  • 2 supported
  • 1 overstated
  • 2 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5OverstatedAdditional analyses confirmed that the variant near EPHA7 reduced its expression, supporting the team's hypothesis that reduced EPHA7 could lead to cells sloughing off from the iris.View evidenceHide evidence

Why this verdict

The profile supports an eQTL association consistent with reduced EPHA7 expression, and it supports using that as regulatory evidence for a mechanistic hypothesis. However, saying additional analyses 'confirmed' that the variant reduced expression and that reduced EPHA7 could lead to iris-cell sloughing goes beyond the abstract-level evidence. The paper profile explicitly says eQTL evidence supports regulatory plausibility but does not prove causal disease mechanisms, and the iris-cell sloughing mechanism is not directly established in the supplied abstract profile.

1

Study evidence

Statistical fine-mapping refined three associated loci to single-variant 95% credible sets.

“We applied statistical fine-mapping”
2

Study evidence

Lead GWAS variants at pigment dispersion syndrome/pigmentary glaucoma loci showed regulatory evidence in eQTL analyses; notably, lead variant(s) were associated with reduced EPHA7 expression.

“assessed expression quantitative trait locus associations for lead variants”
Claim 2 of 5Not coveredPigmentary glaucoma is described as a subtype in which tiny pigment granules break free from the iris and block the eye's drainage system, primarily affecting younger adults.View evidenceHide evidence

Why this verdict

The supplied abstract-level paper profile states that PDS/PG are related to ocular hypertension and glaucomatous optic neuropathy, but it does not verify the story's disease-description details: pigment granules breaking free from the iris, blockage of the eye drainage system, or primary occurrence in younger adults. These may be general background facts, but they are not verifiable from the supplied abstract-depth profile.

Claim 3 of 5Not coveredThe researchers used the All of Us research program, compared more than 500 participants with pigmentary glaucoma or pigment dispersion syndrome against more than 30,000 healthy individuals, and analyzed nearly 900,000 variants on DNA microarrays plus nearly 13 million variants in whole genome sequencing.View evidenceHide evidence

As statedmore than 500 participants; more than 30,000 healthy individuals; nearly 900,000 variants; nearly 13 million variants

Why this verdict

The All of Us source and case/control sample sizes are broadly supported: 572 cases and 37,808 controls for array genotyping, and 537 cases and 35,493 controls for WGS. However, the supplied abstract-level profile does not verify the story's counts of nearly 900,000 array variants or nearly 13 million WGS variants. It also describes controls as individuals without PDS/PG, not necessarily 'healthy individuals.' Because important numerical details in the claim are unavailable at abstract depth, the full claim is not verifiable at this depth.

1

Study evidence

Four loci reached genome-wide significance for association with pigment dispersion syndrome/pigmentary glaucoma in the array-based GWAS: near EPHA7, within TYR (replicated from prior studies), within LINC01138, and near OTX2.

“DESIGN: Case-control study.”
2

Study evidence

Genome-wide significant association near EPHA7 identified in WGS-based GWAS; lead variant(s) show eQTL evidence including association with reduced EPHA7 expression.

“537 cases and 35 493 controls with whole-genome sequencing.”
Claim 4 of 5SupportedYale School of Medicine researchers have discovered new genetic risk factors associated with pigmentary glaucoma, and the findings highlight a novel mechanism that may contribute to the onset of the disease.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that the study identified genetic loci associated with PDS/PG, including a locus near EPHA7, and that eQTL/regulatory evidence generated mechanistic hypotheses involving cell-cell adhesion/signaling. The claim is acceptable because it frames the mechanism as something that 'may contribute,' not as proven causation, though the headline phrasing should be read in light of the paper's caveat that mechanistic causality is not established.

1

Study evidence

Four loci reached genome-wide significance for association with pigment dispersion syndrome/pigmentary glaucoma in the array-based GWAS: near EPHA7, within TYR (replicated from prior studies), within LINC01138, and near OTX2.

“DESIGN: Case-control study.”
2

Study evidence

Genome-wide significant association near EPHA7 identified in WGS-based GWAS; lead variant(s) show eQTL evidence including association with reduced EPHA7 expression.

“537 cases and 35 493 controls with whole-genome sequencing.”
Claim 5 of 5SupportedIn a new study published in Ophthalmology Glaucoma, researchers uncovered further genetic differences linked to pigmentary glaucoma, including variations near EPHA7, a gene involved in how cells move and attach to neighboring cells.View evidenceHide evidence

Why this verdict

The profile supports that the study found genetic associations for PDS/PG, including a genome-wide significant locus near EPHA7, and that the results implicate cell-cell adhesion/signaling pathways. The exact publication venue is not independently assessed here, but the scientific substance of the claim is supported by the supplied profile.

1

Study evidence

Four loci reached genome-wide significance for association with pigment dispersion syndrome/pigmentary glaucoma in the array-based GWAS: near EPHA7, within TYR (replicated from prior studies), within LINC01138, and near OTX2.

“DESIGN: Case-control study.”
2

Study evidence

Genome-wide significant association near EPHA7 identified in WGS-based GWAS; lead variant(s) show eQTL evidence including association with reduced EPHA7 expression.

“537 cases and 35 493 controls with whole-genome sequencing.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The abstract reports genome-wide significant associations at four loci: near EPHA7, within TYR, within LINC01138, and near OTX2.

    The story highlights EPHA7 and generally refers to additional risk variants, but it does not convey the full set of four reported loci or distinguish the previously reported TYR locus from the additional loci.

    From Array-based multi-ancestry case-control GWAS (All of Us); WGS-based multi-ancestry case-control GWAS

  • Statistical fine-mapping refined three associated loci to single-variant 95% credible sets and narrowed the TYR locus to small credible sets.

    The story focuses on discovery of variants and the EPHA7 mechanism, but it does not reflect the fine-mapping result, which is a material part of the paper's post-GWAS evidence.

    From post-GWAS statistical fine-mapping (95% credible sets)

  • The total case count was modest for GWAS, and the abstract does not provide locus-specific odds ratios, P values, allele frequencies, variant identifiers, eQTL effect sizes, or tissue details.

    The story reports participant and variant counts but does not mention the limited quantitative detail available in the abstract or the modest case count, both of which constrain independent appraisal of the strength and specificity of the findings.

    From Array-based multi-ancestry case-control GWAS (All of Us); WGS-based multi-ancestry case-control GWAS; eQTL lookup / func

3 things the story did carry across
  • The paper's core design was an All of Us multi-ancestry case-control GWAS of pigment dispersion syndrome and/or pigmentary glaucoma using array genotyping and WGS datasets.
  • Lead variants showed eQTL regulatory evidence, including association with reduced EPHA7 expression.
  • The paper's mechanistic interpretation is hypothesis-generating: fine-mapping and eQTL evidence prioritize candidate causal variants/genes but do not establish disease-causal mechanisms.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

6

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataIdentify genetic loci associated with pigment dispersion syndrome (PDS) and pigmentary glaucoma (PG) in a large multi-ancestry All of Us case-control dataset using genome-wide association analyses.Array-based multi-ancestry case-control GWAS (All of Us)Expand

In plain English

Array-based multi-ancestry case-control GWAS in the All of Us cohort (572 cases, 37,808 controls) identified four genome-wide significant loci associated with pigment dispersion syndrome and pigmentary glaucoma; statistical fine-mapping narrowed credible sets for several loci and eQTL data provided regulatory support for lead variants.

Key findings

  • Four loci reached genome-wide significance for association with pigment dispersion syndrome/pigmentary glaucoma in the array-based GWAS: near EPHA7, within TYR (replicated from prior studies), within LINC01138, and near OTX2.
  • Statistical fine-mapping refined three loci to single-variant 95% credible sets and narrowed the TYR locus to small credible sets, prioritizing possible causal variants.
“DESIGN: Case-control study.”
What this piece can’t prove
  • Abstract provides aggregate case/control counts but does not report ancestry composition or per-ancestry sample sizes, limiting assessment of transferability across populations.
  • Total number of cases (572) is modest for GWAS of a complex trait, which may limit power to detect additional loci and precision of effect estimates.

3 further details could not be confirmed from the summary.

2secondary dataIdentify genetic loci associated with pigment dispersion syndrome (PDS) and pigmentary glaucoma (PG) in a large multi-ancestry All of Us case-control dataset using genome-wide association analyses.WGS-based multi-ancestry case-control GWASExpand

In plain English

Multi-ancestry WGS-based case-control GWAS in the All of Us cohort (537 cases, 35,493 controls) identified four genome-wide significant loci for pigment dispersion syndrome / pigmentary glaucoma (signals near EPHA7 and OTX2, and within TYR and LINC01138). Statistical fine-mapping narrowed three loci to single-variant 95% credible sets and reduced the TYR locus to small credible sets. Lead variants showed eQTL evidence (including reduced EPHA7 expression). Effect estimates were broadly consistent across genetic ancestry clusters.

Key findings

  • Genome-wide significant association near EPHA7 identified in WGS-based GWAS; lead variant(s) show eQTL evidence including association with reduced EPHA7 expression.
  • Genome-wide significant association within TYR identified and replicated from prior studies; fine-mapping narrowed the TYR locus to small credible sets, prioritizing candidate causal variants.
“537 cases and 35 493 controls with whole-genome sequencing.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

3in silicoPrioritize putative causal variants/genes at associated loci via statistical fine-mapping, cross-trait overlap assessment, and eQTL-based functional annotation.post-GWAS statistical fine-mapping (95% credible sets)Expand

In plain English

The study applied post-GWAS statistical fine-mapping to multi-ancestry GWAS results to construct 95% credible sets for loci associated with pigment dispersion syndrome/pigmentary glaucoma, reporting that three associated loci were refined to single-variant 95% credible sets and that the previously reported TYR locus was narrowed to small credible sets, thereby prioritizing putative causal variants.

Key findings

  • Statistical fine-mapping refined three associated loci to single-variant 95% credible sets.
  • Fine-mapping narrowed the TYR locus to small 95% credible sets, prioritizing possible causal variants at this locus.
“We applied statistical fine-mapping”
What this piece can’t prove
  • Unclear whether fine-mapping leveraged trans-ancestry LD differences explicitly or used ancestry-stratified vs pooled approaches; this affects interpretation of credible set resolution across ancestries.
  • Abstract does not report formal colocalization analyses or full eQTL mapping details tying fine-mapped variants to gene expression.

2 further details could not be confirmed from the summary.

4in silicoPrioritize putative causal variants/genes at associated loci via statistical fine-mapping, cross-trait overlap assessment, and eQTL-based functional annotation.Expand

In plain English

The study states that lead GWAS variants/loci for pigment dispersion syndrome and pigmentary glaucoma were examined for cross-trait overlap as a post-GWAS analytic step, but the abstract provides no details on methods, reference trait datasets, or results of this cross-trait/pleiotropy assessment.

Key findings

  • Cross-trait overlap/pleiotropy assessment was performed on lead GWAS variants/loci for pigment dispersion syndrome and pigmentary glaucoma, but the abstract does not provide outcomes of that assessment.
“examined for cross-trait overlap”
What this piece can’t prove

3 further details could not be confirmed from the summary.

5secondary dataPrioritize putative causal variants/genes at associated loci via statistical fine-mapping, cross-trait overlap assessment, and eQTL-based functional annotation.eQTL lookup / functional annotationExpand

In plain English

The study performed expression quantitative trait locus (eQTL) lookup/association analyses for lead variants from a multi-ancestry GWAS of pigment dispersion syndrome and pigmentary glaucoma, reporting regulatory evidence for several lead variants and specifically an association with reduced EPHA7 expression.

Key findings

  • Lead GWAS variants at pigment dispersion syndrome/pigmentary glaucoma loci showed regulatory evidence in eQTL analyses; notably, lead variant(s) were associated with reduced EPHA7 expression.
“assessed expression quantitative trait locus associations for lead variants”
What this piece can’t prove

3 further details could not be confirmed from the summary.

6in silicoAssess whether effect estimates are consistent across genetic ancestry clusters within the multi-ancestry dataset.PCA-based ancestry-stratified assessmentExpand

In plain English

The study performed principal component analyses to define genetic ancestry clusters and compared GWAS effect estimates across those clusters; the abstract reports that effect estimates were "broadly consistent across genetic ancestry clusters."

Key findings

  • Effect estimates from the multi-ancestry GWAS were reported as broadly consistent across PCA-defined genetic ancestry clusters.
“we performed principal component analyses to assess effect sizes across genetic ancestries.”
What this piece can’t prove
  • The abstract does not specify whether sample sizes per ancestry cluster were sufficient to reliably estimate effect sizes within each group.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 29 candidate papers

And 23 more candidates considered.